浆液性汗腺炎（HS）是毛囊单元的一种慢性炎症性皮肤病。阿达利珠单抗（ADA）是唯一一种经FDA批准用于管理HS的生物制剂，具有抗肿瘤坏死因子（TNF）α的作用。TNF-α还可影响葡萄糖和脂质代谢，通过负向调节新脂肪肌肉激素irisin促进胰岛素抵抗和肥胖。本研究纳入了17名HS患者，自基线和16周时采集了所有患者的血样。通过ELISA检测血浆中irisin水平。与基线相比，在16周ADA治疗后，HS患者的血浆irisin水平显著增加。有趣的是，血浆irisin水平与临床反应呈相关性。皮肤炎症性疾病和代谢性疾病之间的联系引起了极大的关注，为了研究早期发现代谢共病的新生物标志物。irisin是其中最近发现的一种新生物标志物之一。我们检查了一组中度至重度HS患者的抗TNF-α治疗情况，首次证明了一种能够阻断炎症细胞因子的治疗方法可以通过改变irisin水平来影响代谢概况。

Suppurative hidradenitis (HS) is a chronic, inflammatory skin disease of the hair follicle unit. Adalimumab (ADA), an anti-tumor necrosis factor (TNF) alpha, is the only FDA-approved biologic available for the management of HS. TNF-α can also affect glucose and lipid metabolism, promoting insulin resistance and obesity by negatively regulating irisin, a new adipomyokine.A total of 17 HS patients were enrolled in the study. Blood samples were collected from all patients at baseline and week-16. Plasma irisin levels were detected by ELISA assay.Plasma irisin levels were significantly increased after 16 weeks of ADA therapy in HS patients compared to baseline. Interestingly, plasma irisin levels correlated with clinical response.The link between skin inflammatory diseases and metabolic disorders has aroused great interest in order to research new biomarkers able to early identify metabolic comorbidities. Among these emerging biomarkers, irisin is one of the most recently discovered. We examined a group of patients affected by moderate-severe HS treated with anti-TNF-α, demonstrating for the first time how a therapy able to block an inflammatory cytokine can also affect the metabolic profile by modifying levels of irisin.